When was Santen Pharmaceuticals founded?

Santen Pharmaceuticals was founded in 1890.

Where is Santen Pharmaceuticals located?

Santen Pharmaceuticals is headquartered in Osaka, Japan. It is registered at Emeryville, California.

How many employees does Santen Pharmaceuticals have?

As of Jul 31, 2026, the latest employee count at Santen Pharmaceuticals is 1848.

Is Santen Pharmaceuticals a funded company?

Santen Pharmaceuticals is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Santen Pharmaceuticals rank among its competitors?

Santen Pharmaceuticals ranks 4th amongst 19 active competitors, of which 4 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was LabInCube, which secured $9.87M in Mar, 2026.

Who are the top competitors of Santen Pharmaceuticals?

Santen Pharmaceuticals' top competitors include PolyPid, PanTher Therapeutics and Lexaria Bioscience. Among them, LabInCube secured the most recent funding round in March, 2026.

Santen Pharmaceuticals - 2026 Company Profile & Competitors

Santen Pharmaceuticals is a funded company based in Osaka (Japan), founded in 1890. It operates as a Manufacturer of pharmaceutical products for ophthalmology and rheumatology diseases. The company has 19 active competitors, including 4 funded and 2 that have exited. Its top competitors include companies like PolyPid, PanTher Therapeutics and Lexaria Bioscience.

Company Details

Manufacturer of pharmaceutical products for ophthalmology and rheumatology diseases. They are developing drugs for diseases such as corneal conjunctival disease, glaucoma, retinal uvea disease, ocular infections, and others. The company has developed drugs along with Asahi Glass with the help of Asahi's fluorine compound synthesis technology and Santen's advanced screening technology for glaucoma. The company has a pipeline of drugs under development. Their portfolio includes the Sante Series of ophthalmology drugs, medical equipment, dietary supplements and others.

Website: www.santen.com/santen_global
Phone Number: +81 **********
Registered Address: Emeryville, California

Key Metrics

Founded Year

1890

Location

Osaka, Japan

Stage

Funding Raised

Ranked

4^th among 19 active competitors

Employee Count

1,848 as on Jul 31, 2026

Investment & Acquisitions

Eyevance & 8 more

Similar Companies

PolyPid & 22 more

View Santen Pharmaceuticals' full profile

Santen Pharmaceuticals is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Santen Pharmaceutical Co Ltd CIN: T13UF5067L , Japan, Active	Dec 09, 2013	-	-	-
SANTEN INCORPORATED CIN: 680293837 , United States, Active	Dec 31, 1999	-	189 (As on Dec 31, 2024)	-
SANTEN, INC. CIN: 216541995 , United States, Active	Aug 25, 2023	-	-	-

Santen Pharmaceuticals is a funded company.

Santen Pharmaceuticals' employee count trend

Santen Pharmaceuticals has 1,848 employees as of Jul 26. Here is Santen Pharmaceuticals's employee count trend over the years:

Employee count trend for Santen Pharmaceuticals

Uncover Santen Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Santen Pharmaceuticals include PolyPid, PanTher Therapeutics and Lexaria Bioscience. Here is the list of Top 10 competitors of Santen Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	PolyPid 2008, Petah Tikva (Israel), Public	Technology platform enabling controlled and prolonged release of any Active Pharmaceutical Ingredient (API)	$96.7M	Shavit Capital, Aurum Ventures & 6 others	66/100
2nd	PanTher Therapeutics 2014, Cambridge (United States), Series B	Provider of drug delivery system for cancer treatment	$15.4M	CHV, BNSG Capital & 9 others	65/100
3rd	Lexaria Bioscience 2004, Kelowna (Canada), Public	Developer of drug delivery technology designed to improve drug absorption	$45K	-	53/100
4th	Santen Pharmaceuticals 1890, Osaka (Japan), Funding Raised	Manufacturer of pharmaceutical products for ophthalmology and rheumatology diseases	-	-	50/100
5th	Zyl Therapeutics 2017, Greenville (United States), Series B	Developer of hydrogel-derived nanoparticle system for topical applications	$9.42M	VentureSouth, HBS Alumni Angels of Greater New York ... & 13 others	45/100
6th	LabInCube 2021, Cheongju-si (South Korea), Series B	Developer drug-releasing medical devices and medicines	$13.6M	Korea Investment Partners, Metabiomed & 2 others	35/100
7th	JUVIC 2015, Seoul (South Korea), Funding Raised	Developer of a polymer-based drug delivery system	-	Korea Omega Investment Corp, Tech Incubator Program for Startup ... Read more	32/100
8th	Hallux 2012, Laguna Hills (United States), Series B	Provider of subungual drug delivery technology for onychomycosis	$27.2M	Deerfield, OrthoArizona	32/100
9th	Transdermal Delivery Solutions 2011, Palm Beach Gardens (United States), Unfunded	Revolutionizing drug delivery through innovative transdermal technology for improved patient outcomes	-	-	27/100
10th	eMIRAmed 2017, Irvine (United States), Unfunded	Provider of device for transdermal delivery of drugs to the body	-	-	26/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Santen Pharmaceuticals's competitors? Click here to see the top ones

Santen Pharmaceuticals has made 6 investments in companies including BELKIN Vision and International BioMedical Devices. Santen Pharmaceuticals has also acquired 3 companies including Eyevance and InnFocus.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Sep 16, 2020	Acquisition	Eyevance	2017	Fort Worth (United States)
Jul 21, 2020	Investments	BELKIN Vision	2013	Yavne (Israel)
Aug 30, 2016	Investments	International BioMedical Devices	2013	Charleston (United States)